StreetInsider.com News Articles

FDA approves Zoetis single-injection antibiotic for dogs

Tue, 20 Oct 2026 16:42:17 -0400

Zoetis Inc. (NYSE: ZTS) announced that the U.S. Food and Drug Administration has approved Convenia RTU for Dogs (cefovecin injectable suspension) for the treatment of susceptible bacterial skin infections in dogs.

The product delivers up to 14 days of antibiotic treatment in a single subcutaneous injection administered by a veterinary professional. According to the company, the formulation is more concentrated than the existing Convenia (cefovecin sodium) product, allowing the same dose to be delivered in a smaller volume, which the company says makes single-injection treatment more practical for dogs of all sizes, including medium and large breeds.

Convenia RTU for Dogs is

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Tue, 20 Oct 2026 16:42:00 -0400

Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional

Pyoderma – a bacterial skin infection—is one of the top 5 reasons for vet visits for dogs.1
Administration at the veterinary clinic helps dog owners avoid the day-to-day challenge of giving oral antibiotics at home and reduces the risk of missed or irregular doses.
Higher concentration of an antibacterial agent can deliver the same dose of treatment in a smaller volume, helping make single-injection treatment more practical for dogs of all sizes.

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Tue, 20 Oct 2026 16:42:00 -0400

Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional

Pyoderma – a bacterial skin infection—is one of the top 5 reasons for vet visits for dogs.1
Administration at the veterinary clinic helps dog owners avoid the day-to-day challenge of giving oral antibiotics at home and reduces the risk of missed or irregular doses.
Higher concentration of an antibacterial agent can deliver the same dose of treatment in a smaller volume, helping make single-injection treatment more practical for dogs of all sizes.

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Tue, 20 Oct 2026 08:43:45 -0400

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

“Pricing power is at risk in animal health, but diagnostics isn’t like the rest of the industry,” analyst Keith Devas wrote.

Jefferies noted that price and mix now account for all growth in vet and pet services, compared with 50% to 65% before the pandemic.

With muted vet visits, mid-single-digit vet labor inflation and waning owner sentiment, the firm said assuming continued pricing gains for the industry is a

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Tue, 20 Oct 2026 08:43:45 -0400

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

“Pricing power is at risk in animal health, but diagnostics isn’t like the rest of the industry,” analyst Keith Devas wrote.

Jefferies noted that price and mix now account for all growth in vet and pet services, compared with 50% to 65% before the pandemic.

With muted vet visits, mid-single-digit vet labor inflation and waning owner sentiment, the firm said assuming continued pricing gains for the industry is a

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Tue, 20 Oct 2026 08:43:45 -0400

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

“Pricing power is at risk in animal health, but diagnostics isn’t like the rest of the industry,” analyst Keith Devas wrote.

Jefferies noted that price and mix now account for all growth in vet and pet services, compared with 50% to 65% before the pandemic.

With muted vet visits, mid-single-digit vet labor inflation and waning owner sentiment, the firm said assuming continued pricing gains for the industry is a

Jefferies Downgrades Zoetis Inc. (ZTS) to Hold

Tue, 20 Oct 2026 05:09:50 -0400